The patent WO 2003 077914 A1 relates to binimetinib, a MEK inhibitor. This patent application was filed by Array BioPharma Inc. [1].
What is binimetinib used for?
Binimetinib is a targeted therapy used to treat certain types of cancer. It is particularly known for its use in combination with encorafenib for the treatment of patients with BRAF V600E or V600K mutant unresectable or metastatic melanoma [2].
When does the patent for binimetinib expire?
Patent expiry dates are complex and can vary based on original filing dates, any extensions granted (such as for pediatric exclusivity or patent term extensions), and potential patent challenges. DrugPatentWatch.com tracks these details, and specific expiry information for binimetinib patents would be available through their database [3].
Who else is developing binimetinib?
Array BioPharma Inc. originally developed binimetinib. It was later acquired by Pfizer, which now markets the drug [4].
What are the side effects of binimetinib?
Common side effects of binimetinib, often reported when used in combination with encorafenib for melanoma, can include fatigue, nausea, diarrhea, vomiting, abdominal pain, and muscle pain. More serious side effects may also occur, and patients should discuss potential risks with their healthcare provider [2].